Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi Qi Yang Yin Jie Du Fang
- Development stage
- Unknown
- Lead developer
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Yi Qi Yang Yin Jie Du Fang (also known as Yiqi Yangyin Jiedu decoction or YYJD) is a traditional Chinese medicine (TCM) herbal formula developed by Shanghai Traditional Chinese Medicine Hospital and Shanghai University of Traditional Chinese Medicine. It is composed of multiple herbal ingredients, including *Astragalus membranaceus*, *Glehnia root*, *Asparagus root*, *Lilyturf root*, *Glossy privet fruit*, *Spikemoss herb*, *Chinese sage herb*, and others. The formula is designed to strengthen qi, nourish yin, and clear toxic substances. It is primarily investigated as an adjuvant therapy in combination with EGFR tyrosine kinase inhibitors (such as gefitinib or osimertinib) or chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Clinical studies suggest that it may enhance T-lymphocyte activity and killer T-cell function, thereby improving immune function and quality of life while delaying the onset of drug resistance.
- Other names
- YYJDYi Qi Yang Yin Jie Du DecoctionYiqi Yangyin Jiedu DecoctionYiqi Yangyin Jiedu FangYiqi-Yangyin-Jiedu Decoction
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)EGFR (Epidermal growth factor receptor)MMP1 (Matrix metalloproteinase-1)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)PLAU (uPA)SRC (Proto-oncogene tyrosine-protein kinase Src)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on Yi Qi Yang Yin Jie Du Fang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yi Qi Yang Yin Jie Du Fang.